GlassScriptPhysician profile
Thomas R Ortiz
NPI 1750312450
$4,723.47
in general payments reported to CMS, 2019-2025
32 companies · $907 in 2025
The $907 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $518 · 2021: $823 · 2022: $831 · 2024: $185 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $613.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $481.37 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.18 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $435.28 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $395.34 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $291.42 | 2019-2024 | |
| Amarin Pharma, INC. | $246.51 | 2019-2022 | |
| Abbvie INC. | $239.84 | 2019-2025 | |
| Dexcom, INC. | $199.29 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $182.44 | 2019-2024 | Trelegy Ellipta |
| Medtronic, INC. | $133.50 | 2025 | Symplicity G3 |
| Bayer Healthcare Pharmaceuticals INC. | $132.40 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $125.21 | 2019-2022 | |
| Allergan, INC. | $119.07 | 2019-2020 | |
| Cardiovascular Systems INC. | $92.10 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $71.43 | 2021-2022 | |
| Horizon Therapeutics Plc | $66.77 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $62.73 | 2025 | Zoryve |
| Xeris Pharmaceuticals, INC. | $49.57 | 2024-2025 | Gvoke Hypopen |
| Mannkind Corporation | $45.38 | 2019-2025 | |
| Daiichi Sankyo INC. | $42.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.74 | 2021 | |
| Pfizer INC. | $31.91 | 2020-2025 | |
| Phadia US INC. | $31.27 | 2022-2025 | Immunocap |
| Becton, Dickinson and Company | $28.70 | 2019-2020 | |
| Astellas Pharma US INC | $25.40 | 2019 | |
| Ardelyx, INC. | $24.56 | 2025 | Ibsrela |
| Medtronic Minimed, INC. | $22.00 | 2019 | |
| Biotronik INC. | $15.08 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2019 | |
| Gilead Sciences, INC. | $13.64 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.